%0 Journal Article
%A Janssen, Maike
%A Leo, Albrecht
%A Wolf, Cornelia
%A Stenzinger, Miriam
%A Bartenschlager, Marie
%A Brandt, Juliane
%A Sauer, Sandra
%A Schmitt, Michael
%A Dreger, Peter
%A Schlenk, Richard F
%A Denkinger, Claudia M
%A Müller-Tidow, Carsten
%T Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
%J International journal of cancer
%V 155
%N 4
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2024-00974
%P 618-626
%D 2024
%Z 2024 Aug 15;155(4):618-626
%X Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS-CoV-2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS-CoV-2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID-19 infection. Here, we report on a series of 21 immunocompromised patients with COVID-19-most of them hematologic malignancies-treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS-CoV-2-antibody-containing plasma could clear SARS-CoV-2 infection in 16 out of 21 immunocompromised patients even if COVID-19-specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS-CoV-2 infection. Ten patients were major responders defined as an increase delta(d)Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS-CoV-2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10-24.25) to a median value of 29.57 (IQR = 27.55-34.63; p = <.0001) in the major response subgroup. Furthermore, when treated a second time with C/VP, even 4 out of 5 of the initial nonresponders showed an increase in Ct-values from a median value of 23.13 (IQR = 17.75-28.05) to a median value of 32.79 (IQR = 31.75-33.75; p = .013). Our results suggest that C/VP could be a feasible treatment of COVID-19 infection in patients with hematologic malignancies who did not respond to antiviral treatment.
%K COVID‐19 (Other)
%K SARS‐CoV‐2‐antibody containing plasma (Other)
%K prolonged SARS‐CoV‐2 infection (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38721724
%R 10.1002/ijc.34988
%U https://inrepo02.dkfz.de/record/290075